Marathon Asset Management Ltd Sells 19,737 Shares of Teleflex Incorporated $TFX

Marathon Asset Management Ltd reduced its stake in shares of Teleflex Incorporated (NYSE:TFX) by 23.4% in the third quarter, HoldingsChannel reports. The institutional investor owned 64,787 shares of the medical technology company’s stock after selling 19,737 shares during the period. Marathon Asset Management Ltd’s holdings in Teleflex were worth $7,927,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Thurston Springer Miller Herd & Titak Inc. lifted its holdings in shares of Teleflex by 242.9% in the second quarter. Thurston Springer Miller Herd & Titak Inc. now owns 216 shares of the medical technology company’s stock worth $26,000 after buying an additional 153 shares in the last quarter. True Wealth Design LLC increased its holdings in Teleflex by 10,333.3% in the 2nd quarter. True Wealth Design LLC now owns 313 shares of the medical technology company’s stock valued at $37,000 after acquiring an additional 310 shares during the last quarter. Farther Finance Advisors LLC lifted its stake in Teleflex by 151.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 408 shares of the medical technology company’s stock worth $50,000 after purchasing an additional 246 shares in the last quarter. Parallel Advisors LLC boosted its holdings in shares of Teleflex by 43.1% during the 2nd quarter. Parallel Advisors LLC now owns 455 shares of the medical technology company’s stock valued at $54,000 after purchasing an additional 137 shares during the last quarter. Finally, Blue Trust Inc. boosted its holdings in shares of Teleflex by 214.0% during the 3rd quarter. Blue Trust Inc. now owns 493 shares of the medical technology company’s stock valued at $60,000 after purchasing an additional 336 shares during the last quarter. Institutional investors own 95.62% of the company’s stock.

Teleflex Stock Performance

NYSE TFX opened at $122.82 on Monday. The business’s 50 day moving average price is $120.08 and its 200-day moving average price is $121.01. Teleflex Incorporated has a fifty-two week low of $102.58 and a fifty-two week high of $185.94. The company has a market cap of $5.43 billion, a P/E ratio of -16.71, a P/E/G ratio of 1.46 and a beta of 0.95. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.53 and a current ratio of 2.57.

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, November 6th. The medical technology company reported $3.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.38 by $0.29. The company had revenue of $892.90 million during the quarter, compared to the consensus estimate of $892.79 million. Teleflex had a positive return on equity of 15.64% and a negative net margin of 10.28%.Teleflex’s revenue was up 19.4% on a year-over-year basis. During the same period last year, the company earned $3.49 earnings per share. Teleflex has set its FY 2025 guidance at 14.000-14.200 EPS. Sell-side analysts predict that Teleflex Incorporated will post 13.98 earnings per share for the current year.

Teleflex Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, December 15th. Investors of record on Friday, November 14th were paid a dividend of $0.34 per share. The ex-dividend date of this dividend was Friday, November 14th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.1%. Teleflex’s payout ratio is currently -18.50%.

Analyst Upgrades and Downgrades

TFX has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Teleflex in a report on Monday, December 22nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Teleflex in a research note on Tuesday, December 9th. Truist Financial increased their target price on Teleflex from $120.00 to $135.00 and gave the company a “hold” rating in a research report on Thursday, December 18th. Wells Fargo & Company boosted their price target on shares of Teleflex from $114.00 to $139.00 and gave the stock an “equal weight” rating in a research report on Wednesday, December 10th. Finally, Zacks Research downgraded shares of Teleflex from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 30th. One equities research analyst has rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus price target of $142.43.

Teleflex Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.